Susceptibility to infection and disease severity may be increased using angiotensin type-1 receptor blockers (ARBs) and ACE inhibitors (ACEIs), since both increase the viral receptor (ACE2) levels, and thus, targeted therapies to block the ACE2 protein are being considered. Here, ACE2 is linked to infection.